The Daily Raise/September 2, 2026
Funding round
NovaGo Therapeutics raises CHF 24M Series B round
NovaGo Therapeutics (Switzerland) has raised CHF 24M in a Series B round, announced on September 2, 2026. The company is Develops anti-Nogo-A biologics for central nervous system diseases. The round was led by Neurimmune, with participation from Pureos, Swiss Paraplegic Foundation, Wings for Life.
NovaGo Therapeutics raised CHF 24 million to advance its lead program into a randomized proof-of-concept study for acute spinal cord injury.
Company
NovaGo Therapeutics
Amount
CHF 24M (~$29.5M)
Round
Series B
Sector
Biotechnology
Country
Switzerland
Announced
September 2, 2026
Track every raise, every day
This deal appeared in The Daily Raise, September 2, 2026. Get the next edition in your inbox.
Just raised too?
Turn your funding news into guaranteed media coverage while the momentum lasts.